Global Acute Migraine Medication Market Size, Share and Trends Analysis Report, by Platform (Pain Relieving Medication and Preventive Medication), and by Route of Administration (Oral, Injectable and Nasal Sprays), Forecast Period (2022-2028)

The global acute migraine medication market is anticipated to grow at a CAGR of 6.1% during the forecast period (2022-2028). Migraine medications for acute migraine ergot alkaloids, triptans, and other migraine treatments are available on the market. The market is growing as people become more aware of the different types of migraines and the various treatment choices available. The prevalence of migraines is a major market driver. Many people nowadays suffer from migraine headaches. Every year, the number of people who suffer from severe headaches increases. For instance, in July 2021, according to the GaonConnection article, in India, more than 213 million people were diagnosed with migraines in 2019, with women accounting for 60% of the cases. Migraine pain is caused by lifestyle changes, bad eating habits, and underlying health concerns.

 

Furthermore, people who already suffer from migraines must take effective migraine prevention medications. The market growth is likely to be boosted by the testing of migraine medications for the treatment of coronavirus disease (COVID-19). For instance, in February 2022, Biohaven Pharmaceutical Holding Business Ltd., a clinical-stage biopharmaceutical company that was testing Zavegepant for the treatment of acute migraines, has started a clinical trial on the same medicine to attenuate COVID-19 patients’ neuro-immune effects.

 

The approval of a new class of medicine specifically developed to treat migraines by the US Food and Drug Administration has had a favourable impact on the market. For instance, in September 2021, Qulipta (atogepant), an oral medication developed by AbbVie, has been approved by the US Food and Drug Administration (FDA) as a preventive treatment for episodic migraine in adults. Qulipta is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) developed specifically for the treatment of episodic migraines.

 

Additionally, in January 2020, Eli Lilly and co., announced that REYVOWTM (lasmiditan) C-V 50 mg and 100 mg tablets, an oral drug for the immediate treatment of migraine in adults with or without aura, are available for prescription as well as available in pharmacies. REYVOW works in a unique way compared to conventional migraine acute therapies. REYVOW is the first and only FDA-approved ditan, a 5-HT1F receptor agonist that is thought to act both centrally and peripherally, and it is a novel kind of acute migraine medication.

 

Women are more likely than men to experience migraine pain. According to the Migraine Association of Ireland, the global population in 2018 had a 3:1 ratio of female migraineurs to male migraineurs. This is due to fluctuations in estrogen levels in women, particularly during menstruation. Hormonal medicines, such as oral contraceptives and hormone replacement therapy, can also make migraines worse in women. As a result, the market for migraine medications is expected to rise as the global female population grows.

 

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Platform
  • By  Route of Administration
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Abbott, Allergan, Astra Zeneca ,Eisai Co., Ltd.,GlaxoSmithKline Plc., among others.

 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Acute Migraine Medication Market Report by Segment

By Platform

• Pain Relieving Medication
• Preventive Medication

By Route of Administration

• Oral
• Injectable
• Nasal Sprays

 

Global Acute Migraine Medication Market Report by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa